Form 4: Pfizer CEO Bourla Acquires Phantom Stock Units

Pfizer Inc. Chairman and CEO Albert Bourla reported the acquisition of 1,630 phantom stock units as part of a deferred compensation plan.

Summary

• Albert Bourla, Chairman & CEO of Pfizer Inc. (PFE), acquired 1,630 phantom stock units.
• The transaction occurred on March 13, 2026, and was made pursuant to a Rule 10b5-1(c) plan.
• Each unit represents one phantom share of common stock and was acquired at a price of $26.58.
• These units are part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• The units are settled in cash following the reporting person's separation from service and may be transferred into an alternative investment account at any time.
• Following this transaction, Bourla beneficially owns 759,400 derivative securities (phantom stock units).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and alignment with long-term company performance, without indicating any significant new strategic direction or financial health change.

Positives

• The acquisition of additional phantom stock units by the CEO indicates continued participation in the company's deferred compensation plan.
• The transaction aligns the CEO's long-term interests with shareholder value, as the units are tied to common stock performance.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance. It is a report of a past transaction.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the acquisition of phantom stock units through deferred compensation plans, are common in the pharmaceutical industry. These transactions typically reflect executive participation in long-term incentive programs rather than discretionary open-market purchases, and are generally viewed as a standard component of executive remuneration.

Comparison to Industry Standards

• This type of deferred compensation plan, where executives acquire phantom stock units that settle in cash upon separation, is a common practice among large-cap pharmaceutical companies like Johnson & Johnson (JNJ) and Merck & Co. (MRK).
• These plans are designed to align executive incentives with long-term shareholder value and retention, similar to how other industry leaders structure their executive compensation packages.

Related Party Transactions

• The acquisition of phantom stock units under a company-sponsored deferred compensation plan can be considered a related-party transaction, as it involves the company and its CEO.

Stakeholder Impact

• Shareholders: The transaction aligns the CEO's long-term financial interests with the company's stock performance, potentially fostering a focus on sustained value creation.

Key Dates

Recommendation

This Form 4 filing reports a routine acquisition of phantom stock units by the CEO as part of a deferred compensation plan, which is a standard executive compensation practice. It does not provide new information that would significantly alter the investment thesis for Pfizer Inc. Therefore, a "hold" recommendation is appropriate, as the filing does not present a compelling reason to buy or sell based solely on this transaction.

Keywords

Pfizer, PFE, Albert Bourla, Insider Transaction, Form 4, Phantom Stock Units, Deferred Compensation, CEO, Executive Compensation